Salbutamol

• A double-dummy, double-blind, randomized, active controlled, two-way cross-over study with 12-week treatment duration per period, to evaluat… Pending
  2022-502365-26-00 Phase III 4 countries Novartis Pharma AG
• A study to investigate airway inflammation with dupilumab subcutaneously in participants aged ≥40 to ≤85 years with chronic obstructive pulm… Recruiting
  2025-521268-37-00 Phase IV 10 countries Sanofi-Aventis Recherche & Developpement
• CPAAARI-Therapeutic efficacy comparison of a six-month treatment by itraconazole and nebulised Ambisome® versus treatment by itraconazole al… Recruiting
  2024-517004-11-00 Phase III 1 country Centre Hospitalier Universitaire De Poitiers
• A Study Evaluating the Efficacy of Budesonide, Glycopyrronium, and Formoterol Fumarate Metered-Dose Inhaler on Cardiopulmonary Outcomes in C… Recruiting
  2023-507407-59-00 Phase III 16 countries Astrazeneca AB
• A study to evaluate the efficacy and safety of QMF149 (indacaterol acetate/mometasone furoate) versus Budesonide in children from 6 to less … Recruiting
  2022-501899-26-00 Phase III 9 countries Novartis Pharma AG
• Efficacy, Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Glycopyrronium (Bromide) in Children (6 to Less Than 12 Years) With… Recruiting
  2024-511382-11-00 Phase II 4 countries Novartis Pharma AG
• Study to treat adult patients with Very High-Risk T-cell Acute Lymphoblastic Leukemia (ALL) with Daratumumab in addition to the National ALL… Ended
  2024-511627-34-00 Phase II 1 country Fondazione Gimema Franco Mandelli Onlus
• A study to investigate the effect on lung function of an approved COPD treatment (BGF, with HFA propellant) compared to BGF formulated with… Ended
  2023-506565-57-00 Phase III 3 countries Astrazeneca AB
• "Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a History of Exacerbations (MIRANDA)" Ended
  2023-505543-39-00 Phase III 12 countries Astrazeneca AB
• A 12-week double-blind, multicentre, randomised, active-controlled, 2-arm, parallel-group clinical trial to evaluate the safety of CHF5993 p… Ended
  2023-503333-22-00 Phase III 11 countries Chiesi Farmaceutici S.p.A.
• A Study to Evaluate the Effect of BGF MDI, BFF MDI and Placebo MDI on Exercise Parameters in Participants with COPD Ended
  2022-502274-16-00 Phase III/IV 2 countries AstraZeneca AB
• Long-term extension study of ligelizumab in food allergy Ended
  2022-502366-25-00 Phase III 5 countries Novartis Pharma AG
• Long-term Efficacy and Safety of Tozorakimab in Participants with Chronic Obstructive Pulmonary Disease with a History of Exacerbations. Ended
  2022-501063-41-00 Phase III 17 countries Astrazeneca AB
• A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study to Assess Efficacy and Safety of Atuliflapon Given Orally Once Daily for Twel… Ended
  2023-509243-27-00 Phase II 10 countries AstraZeneca AB
• Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler in Patients with Inadequately Controlled Asthma Ended
  2024-513568-24-00 Phase III 3 countries AstraZeneca AB
• Congenital myopathy intervention study Ended
  2024-512027-36-00 Phase IV 1 country Vaestra Goetalandsregionen
• "A Variable Length Study to Evaluate the Efficacy and Safety of Budesonide/Glycopyrronium/Formoterol inhaler in Adults and Adolescents with … Ended
  2023-505787-11-00 Phase III 6 countries AstraZeneca AB
• A Variable Length Study to Evaluate the Efficacy and Safety of Budesonide/Glycopyrronium/Formoterol inhaler in Adults and Adolescents with S… Ended
  2023-505786-88-00 Phase III 5 countries Astrazeneca AB
• InSaKa trial: Insulin dextrose infusion versus nebulized salbutamol versus combination of salbutamol and insulin dextrose in acute hyperkale… Ended
  2024-514889-40-00 Phase IV 1 country Centre Hospitalier Universitaire De Nantes

Showing 1–19 of 19 trials